Soleno Therapeutics slips after report of patient death

Shares of drugmaker Soleno Therapeutics SLNO.O fall 12% to $61.15

Co says a 17-year-old patient with Prader-Willi Syndrome and multiple health issues died from pulmonary embolus, a condition caused by a blood clot blocking blood flow in the lungs, while taking Vykat XR

The treating physician and Soleno say the death was not related to its rare genetic disorder drug

Last month, Scorpion Capital said it has taken a short position on Soleno citing issues with the Vykat XR

In March, FDA approved Vykat XR to treat a rare genetic disorder called Prader-Willi syndrome

Including session's move, stock up 36% YTD